Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Spirtas is active.

Publication


Featured researches published by Robert Spirtas.


Cancer Research | 2006

Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years

Kathleen E. Malone; Janet R. Daling; David R. Doody; Li Hsu; Leslie Bernstein; Ralph J. Coates; Polly A. Marchbanks; Michael S. Simon; Jill A. McDonald; Sandra A. Norman; Brian L. Strom; Ronald T. Burkman; Giske Ursin; Dennis Deapen; Linda K. Weiss; Suzanne G. Folger; Jennifer Madeoy; Danielle M. Friedrichsen; Nicola M. Suter; Mariela Humphrey; Robert Spirtas; Elaine A. Ostrander

Although well studied in families at high-risk, the roles of mutations in the BRCA1 and BRCA2 genes are poorly understood in breast cancers in the general population, particularly in Black women and in age groups outside of the very young. We examined the prevalence and predictors of BRCA1 and BRCA2 mutations in 1,628 women with breast cancer and 674 women without breast cancer who participated in a multicenter population-based case-control study of Black and White women, 35 to 64 years of age. Among cases, 2.4% and 2.3% carried deleterious mutations in BRCA1 and BRCA2, respectively. BRCA1 mutations were significantly more common in White (2.9%) versus Black (1.4%) cases and in Jewish (10.2%) versus non-Jewish (2.0%) cases; BRCA2 mutations were slightly more frequent in Black (2.6%) versus White (2.1%) cases. Numerous familial and demographic factors were significantly associated with BRCA1 and, to a lesser extent, BRCA2 carrier status, when examined individually. In models considering all predictors together, early onset ages in cases and in relatives, family history of ovarian cancer, and Jewish ancestry remained strongly and significantly predictive of BRCA1 carrier status, whereas BRCA2 predictors were fewer and more modest in magnitude. Both the combinations of predictors and effect sizes varied across racial/ethnic and age groups. These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.


Obstetrics & Gynecology | 2002

Hormone replacement therapy regimens and breast cancer risk

Linda K. Weiss; Ronald T. Burkman; Kara L. Cushing-Haugen; Lynda F. Voigt; Michael S. Simon; Janet R. Daling; Sandra A. Norman; Leslie Bernstein; Giske Ursin; Polly A. Marchbanks; Brian L. Strom; Jesse A. Berlin; Anita L. Weber; David R. Doody; Phyllis A. Wingo; Jill A. McDonald; Kathleen E. Malone; Suzanne G. Folger; Robert Spirtas

OBJECTIVE Hormone replacement therapy (HRT) has increased in the United States over the past 2 decades in response to reports of long‐term health benefits. A relationship between HRT and breast cancer risk has been observed in a number of epidemiological studies. In 2002, the Womens Health Initiative Randomized Controlled Trial reported an association between continuous combined HRT and breast cancer risk. The objective of this study was to examine the association between breast cancer risk and HRT according to regimen and duration and recency of use. METHODS A multicenter, population‐based, case‐control study was conducted in five United States metropolitan areas from 1994 to 1998. Analyzed were data from 3823 postmenopausal white and black women (1870 cases and 1953 controls) aged 35–64 years. Odds ratios (ORs) were calculated as estimates of breast cancer risk using standard, unconditional, multivariable logistic regression analysis. Potential confounders were included in the final model if they altered ORs by 10% or more. Two‐sided P values for trend were computed from the likelihood ratio statistic. RESULTS Continuous combined HRT was associated with increased breast cancer risk among current users of 5 or more years (1.54; 95% confidence interval 1.10, 2.17). Additionally, a statistically significant trend indicating increasing breast cancer risk with longer duration of continuous combined HRT was observed among current users (P = .01). There were no positive associations between breast cancer risk and other HRT regimens. CONCLUSION Our data suggest a positive association between continuous combined HRT and breast cancer risk among current, longer term users. Progestin administered in an uninterrupted regimen may be a contributing factor. Risk dissipates once use is discontinued.


Cancer | 2002

Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma†

Janet R. Daling; Kathleen E. Malone; David R. Doody; Lynda F. Voigt; Leslie Bernstein; Ralph J. Coates; Polly A. Marchbanks; Sandra A. Norman; Linda K. Weiss; Giske Ursin; Jesse A. Berlin; Ronald T. Burkman; Dennis Deapen; Suzanne G. Folger; Jill A. McDonald; Michael S. Simon; Brian L. Strom; Phyllis A. Wingo; Robert Spirtas

The incidence of invasive lobular carcinoma has been increasing among postmenopausal women in some parts of the United States. Part of this may be due to changes in classification over time. However, the use of combined (estrogen and progestin) hormone replacement therapy (CHRT) also has increased during the last decade and may account in part for the increase in invasive lobular breast carcinoma.


Annals of Epidemiology | 2002

The NICHD Women's Contraceptive and Reproductive Experiences Study: Methods and Operational Results

Polly A. Marchbanks; Jill A. McDonald; Hoyt G. Wilson; Nancy M. Burnett; Janet R. Daling; Leslie Bernstein; Kathleen E. Malone; Brian L. Strom; Sandra A. Norman; Linda K. Weiss; Jonathan M. Liff; Phyllis A. Wingo; Ronald T. Burkman; Suzanne G. Folger; Jesse A. Berlin; Dennis Deapen; Giske Ursin; Ralph J. Coates; Michael S. Simon; Michael F. Press; Robert Spirtas

PURPOSE This paper presents methods and operational results of a population-based case-control study examining the effects of oral contraceptive use on breast cancer risk among white and black women aged 35-64 years in five U.S. locations. METHODS Cases were women newly diagnosed with breast cancer during July 1994 through April 1998. Controls were identified through random digit dialing (RDD) using unclustered sampling with automated elimination of nonworking numbers. Sampling was density-based, with oversampling of black women. In-person interviews were conducted from August 1994 through December 1998. Blood samples were obtained from subsets of cases and controls, and tissue samples were obtained from subsets of cases. A computerized system tracked subjects through study activities. Special attention was devoted to minimizing exposure misclassification, because any exposure-disease associations were expected to be small. RESULTS An estimated 82% of households were screened successfully through RDD. Interviews were completed for 4575 cases (2953 whites; 1622 blacks) and 4682 controls (3021 whites; 1661 blacks). Interview response rates for cases and controls were 76.5% and 78.6%, respectively, with lower rates for black women and older women. CONCLUSIONS The methodologic details of this large collaboration may assist researchers conducting similar investigations.


British Journal of Cancer | 2005

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology

Giske Ursin; Leslie Bernstein; Sarah J. Lord; Roksana Karim; Dennis Deapen; Michael F. Press; Janet R. Daling; Sandra A. Norman; Jonathan M. Liff; Polly A. Marchbanks; Suzanne G. Folger; Michael S. Simon; Brian L. Strom; Ronald T. Burkman; Linda K. Weiss; Robert Spirtas

Reproductive factors are associated with reduced risk of breast cancer, but less is known about whether there is differential protection against subtypes of breast cancer. Assuming reproductive factors act through hormonal mechanisms they should protect predominantly against cancers expressing oestrogen (ER) and progesterone (PR) receptors. We examined the effect of reproductive factors on subgroups of tumours defined by hormone receptor status as well as histology using data from the NIHCD Womens Contraceptive and Reproductive Experiences (CARE) Study, a multicenter case–control study of breast cancer. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) as measures of relative risk using multivariate unconditional logistic regression methods. Multiparity and early age at first birth were associated with reduced relative risk of ER + PR + tumours (P for trend=0.0001 and 0.01, respectively), but not of ER − PR − tumours (P for trend=0.27 and 0.85), whereas duration of breastfeeding was associated with lower relative risk of both receptor-positive (P for trend=0.0002) and receptor-negative tumours (P=0.0004). Our results were consistent across subgroups of women based on age and ethnicity. We found few significant differences by histologic subtype, although the strongest protective effect of multiparity was seen for mixed ductolobular tumours. Our results indicate that parity and age at first birth are associated with reduced risk of receptor-positive tumours only, while lactation is associated with reduced risk of both receptor-positive and -negative tumours. This suggests that parity and lactation act through different mechanisms. This study also suggests that reproductive factors have similar protective effects on breast tumours of lobular and ductal origin.


Cancer Epidemiology, Biomarkers & Prevention | 2006

Relationship between Established Breast Cancer Risk Factors and Risk of Seven Different Histologic Types of Invasive Breast Cancer

Christopher I. Li; Janet R. Daling; Kathleen E. Malone; Leslie Bernstein; Polly A. Marchbanks; Jonathan M. Liff; Brian L. Strom; Michael S. Simon; Michael F. Press; Jill A. McDonald; Giske Ursin; Ronald T. Burkman; Dennis Deapen; Robert Spirtas

Background: Important differences in the contributions of certain exposures to the risks of ductal versus lobular breast carcinomas have been observed, but few studies have evaluated the relationships between established breast cancer risk factors and other histologic types. Methods: Information on family history of cancer and reproductive, hormonal, anthropometric, and lifestyle characteristics were collected in a multicenter population-based case-control study consisting of 3,463 ductal, 274 lobular, 261 ductal-lobular, 91 medullary, 77 tubular, 70 comedo, and 61 mucinous invasive breast carcinoma cases (ages 35-64 years, newly diagnosed 1994-1998) and 4,682 controls. Associations between each of these histologic types and various exposures were evaluated using polytomous regression. Results: Heterogeneity in the risks of different histologic types of breast cancer was observed for three exposures: menopausal hormone use, body mass index (BMI), and alcohol consumption. Specifically, current use of unopposed estrogen was associated with a reduced risk of ductal carcinoma and increased risk of comedocarcinoma, and current use of estrogen and progestin was associated with elevated risks of ductal-lobular and tubular carcinomas. Among postmenopausal women, BMI was only inversely related to risk of ductal-lobular carcinoma, and alcohol use was only positively related to risk of lobular carcinoma. Conclusions: Variations in the associations between known breast cancer risk factors and risk of different breast cancer histologies were observed. Although these findings require confirmation, and the analyses of some histologic groups were limited by small sample sizes, they provide some insight into the different etiologies of various histologic subtypes of breast cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(5):946–54)


Cancer Epidemiology, Biomarkers & Prevention | 2008

Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control Study

Sarah J. Lord; Leslie Bernstein; Karen A. Johnson; Kathleen E. Malone; Jill A. McDonald; Polly A. Marchbanks; Michael S. Simon; Brian L. Strom; Michael F. Press; Suzanne G. Folger; Ronald T. Burkman; Dennis Deapen; Robert Spirtas; Giske Ursin

Background: Early age at first birth and multiparity reduce the risk of estrogen receptor-progesterone receptor (ERPR)–positive breast cancer, whereas breastfeeding reduces the risk of both ERPR-positive and ERPR-negative cancers. Methods: We used multivariable logistic regression analysis to investigate whether age at first birth (<25 or ≥25 years) and breastfeeding (ever/never) modify the long-term effect of parity on risk of ERPR-positive and ERPR-negative cancer using 1,457 incident breast cancer cases and 1,455 controls ages ≥55 years who participated in the Womens Contraceptive and Reproductive Experiences Study. Results: Women who gave birth before age 25 years had a 36% reduced risk of breast cancer compared with nulligravida that was not observed for women who started their families at an older age (Pheterogeneity = 0.0007). This protective effect was restricted to ERPR-positive breast cancer (Pheterogeneity = 0.004). Late age at first birth increased the risk of ERPR-negative cancers. Additional births reduced the risk of ERPR-positive cancers among women with an early first birth (Ptrend = 0.0001) and among women who breastfed (Ptrend = 0.004) but not among older mothers or those who never breastfed. In women with a late first birth who never breastfed, multiparity was associated with increased risk of breast cancer. Conclusions: These findings suggest that the effect of parity on a womans long-term risk of breast cancer is modified by age at first full-term pregnancy and possibly by breastfeeding. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1723–30)


Cancer | 2004

Reproductive factors and risk of breast carcinoma in a study of white and African-American women.

Giske Ursin; Leslie Bernstein; Yaping Wang; Sarah J. Lord; Dennis Deapen; Jonathan M. Liff; Sandra A. Norman; Linda K. Weiss; Janet R. Daling; Polly A. Marchbanks; Kathleen E. Malone; Suzanne G. Folger; Jill A. McDonald; Ronald T. Burkman; Michael S. Simon; Brian L. Strom; Robert Spirtas

Few studies have investigated the association between reproductive factors and the risk of breast carcinoma among African‐American women. The authors assessed whether the number of full‐term pregnancies, age at first full‐term pregnancy, and total duration of breastfeeding were associated with similar relative risk estimates in white and African‐American women in a large multicenter, population‐based case–control study of breast carcinoma.


Cancer Research | 2010

Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study

Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda K. Weiss; Polly A. Marchbanks; Robert Spirtas; Giske Ursin; Ronald T. Burkman; Michael S. Simon; Kathleen E. Malone; Brian L. Strom; Jill A. McDonald; Michael F. Press; Leslie Bernstein

Epidemiologic studies suggest that some hormone-related risk factors in breast cancer differentially influence risk for disease subtypes classified by the status of the estrogen and progesterone receptors (ER/PR). However, it remains unclear whether human epidermal growth factor receptor 2 (HER2) or p53 expression status further differentiates these exposure-risk group associations. We evaluated the associations of oral contraceptive (OC) use and reproductive factors with incident invasive breast cancer subtypes among 1,197 population-based cases and 2,015 controls from the Los Angeles County or Detroit components of the Womens Contraceptive and Reproductive Experiences Study. Case-control comparisons by ER/PR/HER2/p53 status were conducted by multivariable polychotomous unconditional logistic regression methods. We found that OC use was not associated with any breast cancer subtype as defined by ER/PR/HER2/p53 status, except for a 2.9-fold increased risk of so-called triple-negative tumors (ER(-)/PR(-)/HER2(-)) among women of 45 to 64 years of age who started OC use before age 18. Parity was associated with a decreased risk of luminal A (ER(+) or PR(+), HER2(-)), luminal B (ER(+) or PR(+)/HER2(+)), and ER(-)/PR(-)/HER2(+) tumors. Age at first full-term pregnancy was positively associated with luminal A tumors among older women. Neither of these reproductive factors was associated with triple-negative tumors. Long duration of breast-feeding lowered the risk of triple-negative and luminal A tumors. p53 status did not define further differential risk patterns. Our findings offer evidence of differences in the hormone-related risk factors between triple-negative cancers and other ER/PR/HER2-defined subtypes of breast cancer.


Cancer Epidemiology, Biomarkers & Prevention | 2010

A Case-Control Study of Body Mass Index and Breast Cancer Risk in White and African-American Women

Paula Berstad; Ralph J. Coates; Leslie Bernstein; Suzanne G. Folger; Kathleen E. Malone; Polly A. Marchbanks; Linda K. Weiss; Jonathan M. Liff; Jill A. McDonald; Brian L. Strom; Michael S. Simon; Dennis Deapen; Michael F. Press; Ronald T. Burkman; Robert Spirtas; Giske Ursin

Objective: Large body size has been associated with decreased risk of breast cancer in premenopausal women but with increased risk in postmenopausal women. Limited information is available about African-American women and differences by estrogen and progesterone receptor status. Methods: We analyzed data from the Womens Contraceptive and Reproductive Experiences Study among 3,997 white and African-American breast cancer case patients diagnosed in 1994 to 1998 and 4,041 control participants ages 35 to 64 years. We calculated multivariate odds ratios (OR) as measures of relative risk of breast cancer associated with self-reported body mass index (BMI) at age 18 and 5 years before diagnosis (recent BMI). Results: Risk tended to decrease with increasing BMI at age 18 years in all women [ORBMI ≥ 25 kg/m2 versus < 20 kg/m2 = 0.76; 95% confidence interval (CI), 0.63-0.90; Ptrend = 0.005] and with recent BMI in premenopausal women (ORBMI ≥ 35 kg/m2 versus < 25 kg/m2 = 0.81; 95% CI, 0.61-1.06; Ptrend = 0.05), unmodified by race. Among postmenopausal white but not African-American women, there was an inverse relation between recent BMI and risk. High recent BMI was associated with increased risk of estrogen receptor– and progesterone receptor–positive tumors among postmenopausal African-American women (ORBMI ≥ 35 kg/m2 versus < 25 kg/m2 = 1.83; 95% CI, 1.08-3.09; Ptrend = 0.03). Conclusion: Among women at age 35 to 64 years, BMI at age 18 years is inversely associated with risk of breast cancer, but association with recent BMI varies by menopause status, race, and hormone receptor status. Impact: Our findings indicate that studies of BMI and breast cancer should consider breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 19(6); 1532–44. ©2010 AACR.

Collaboration


Dive into the Robert Spirtas's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Polly A. Marchbanks

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Brian L. Strom

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kathleen E. Malone

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Jill A. McDonald

New Mexico State University

View shared research outputs
Top Co-Authors

Avatar

Suzanne G. Folger

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Giske Ursin

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Linda K. Weiss

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge